固本解毒祛瘀法联合化疗治疗晚期非小细胞肺癌临床研究

Clinical Study on Guben Jiedu Quyu Method Combined with Chemotherapy forAdvanced Non-Small Cell Lung Cancer

目的:观察固本解毒祛瘀法联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将78例晚期NSCLC患者按照随机奇偶法分为对照组与研究组各39例。对照组接受化疗治疗,研究组在对照组基础上联合固本解毒祛瘀法治疗。比较2组临床疗效、不良反应发生率,并比较2组治疗前后血清肿瘤标志物、免疫因子水平。结果:治疗后,研究组治疗总有效率69.23%,高于对照组46.15%(P<0.05)。治疗前,2组血清神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)以及癌抗原(CA125)水平比较,差异无统计学意义(P>0.05);治疗后,2组NSE、CEA、CA125水平均下降(P<0.05),且研究组低于对照组(P<0.05)。治疗前,2组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较,差异无统计学意义(P>0.05);治疗后,2组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均升高(P<0.05),CD8^(+)均下降(P<0.05),且研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组(P<0.05),CD8^(+)低于对照组(P<0.05)。治疗期间,研究组恶心呕吐、白细胞降低、血小板减少、肝功能损害等不良反应发生率均明显低于对照组(P<0.05)。结论:固本解毒祛瘀法联合化疗治疗晚期NSCLC可有效降低血清肿瘤标志物水平,提高机体免疫机能,安全性高,疗效显著。

Objective:To observe the clinical effect of Guben Jiedu Quyu Method combined with chemotherapy for advanced non-small cell lung cancer(NSCLC).Methods:A total of 78 cases of patients with advanced NSCLC were randomly divided into the control group and the study group according to the odd-even number grouping method,with 39 cases in each group.The control group was treated with chemotherapy,and the study group was additionally treated with Guben Jiedu Quyu Method based on the treatment of the control group.The clinical effects and the incidence of adverse reactions were compared between the two groups;the levels of tumor markers and immune factors in serum were compared before and after treatment between the two groups.Results:After treatment,the total effective rate was 69.23%in the study group,higher than that of 46.15%in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of neuron-specific enolase(NSE),carcinoembryonic antigen(CEA),and cancer antigen(CA125)in serum between the two groups(P>0.05).After treatment,the levels of NSE,CEA,and CA125 in the two groups were decreased(P<0.05),and the above levels in the study group were lower than those in the control group(P<0.05).Befor treatment,there was no significant difference being found in the comparison of CD3^(+),CD4^(+),CD8^(+),andCD4^(+)/CD8^(+) between the two groups (P>0.05). After treatment,CD3^(+),CD4^(+),and CD4^(+)/CD8^(+) in the twogroups were increased (P<0.05),and CD8^(+) was decreased (P<0.05);CD3^(+),CD4^(+),and CD4^(+)/CD8^(+) in thestudy group were higher than those in the control group (P<0.05), and CD8 + was lower than that in thecontrol group (P<0.05). During treatment, the incidence of nausea and vomiting, leukopenia,thrombocytopenia, liver damage and other adverse reactions in the study group was significantly lowerthan that in the control group (P<0.05). Conclusion: Guben Jiedu Quyu Method combined withchemotherapy for advanced NSCLC can effectively reduce the levels of serum tumor markers and improvethe immune function,with high safety and a significant curative effect.